Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

Jorge Cortes, Susan O'Brien, Javier Loscertales, Hagop Kantarjian, Francis Giles, Deborah Thomas, Charles Koller, Michael Keating

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL. METHODS. Thirty-one patients with CLL and anemia or thrombocytopenia of presumed autoimmune etiology were treated with CsA at a dose of 300 mg/day. Sixteen patients (52%) had anemia (hemoglobin ≤ 11 g/dL) and 29 patients (94%) had thrombocytopenia (platelet count ≤ 100 × 109/L). Seventeen patients (55%) had cytopenia that developed during the course of treatment with fludarabine-based regimens. Nineteen patients (61%) had received prior therapy for this complication using steroids, intravenous immunoglobulin, and/or splenectomy. RESULTS. Eighteen patients (62%) with thrombocytopenia and 10 patients (63%) with anemia had a major response defined as an increase in the platelet count ≥ 50 × 109/L or an increase in hemoglobin ≥ 3 g/dL. The median time to initial response was 3 weeks (range, 1÷-13 weeks) and the median time to best response was 10.5 weeks (range, 1÷-48 weeks). The median duration of response was 10 months (range, 1÷-39+ months). Three patients with fludarabine-associated cytopenias were able to receive further therapy with fludarabine with a lesser decrease in the platelet count. A modest decrease in the tumor burden was observed in six patients. The most common toxicity was ≤ Grade 2 (according to the National Cancer Institute's Common Toxicity Criteria) elevation of creatinine, which was observed in 6 patients (19%). Three patients developed opportunistic infections. CONCLUSIONS. CsA is an effective alternative for the treatment of anemia or thrombocytopenia of suspected autoimmune etiology, including those cases occurring in the course of treatment with fludarabine. A modest antileukemic effect was observed in some patients.

Original languageEnglish (US)
Pages (from-to)2016-2022
Number of pages7
JournalCancer
Volume92
Issue number8
DOIs
StatePublished - Oct 15 2001
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclosporine
Anemia
Therapeutics
Idiopathic Thrombocytopenic Purpura
Platelet Count
Thrombocytopenia
Hemoglobins
Pure Red-Cell Aplasia
National Cancer Institute (U.S.)
Intravenous Immunoglobulins
Opportunistic Infections
Splenectomy
Tumor Burden
Creatinine
Steroids

Keywords

  • Anemia
  • Chronic lymphocytic leukemia
  • Cyclosporine A
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. / Cortes, Jorge; O'Brien, Susan; Loscertales, Javier; Kantarjian, Hagop; Giles, Francis; Thomas, Deborah; Koller, Charles; Keating, Michael.

In: Cancer, Vol. 92, No. 8, 15.10.2001, p. 2016-2022.

Research output: Contribution to journalArticle

Cortes, J, O'Brien, S, Loscertales, J, Kantarjian, H, Giles, F, Thomas, D, Koller, C & Keating, M 2001, 'Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia', Cancer, vol. 92, no. 8, pp. 2016-2022. https://doi.org/10.1002/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E
Cortes, Jorge ; O'Brien, Susan ; Loscertales, Javier ; Kantarjian, Hagop ; Giles, Francis ; Thomas, Deborah ; Koller, Charles ; Keating, Michael. / Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. In: Cancer. 2001 ; Vol. 92, No. 8. pp. 2016-2022.
@article{ee34fdb29578476fbe9d929a604afb3b,
title = "Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia",
abstract = "BACKGROUND. Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL. METHODS. Thirty-one patients with CLL and anemia or thrombocytopenia of presumed autoimmune etiology were treated with CsA at a dose of 300 mg/day. Sixteen patients (52{\%}) had anemia (hemoglobin ≤ 11 g/dL) and 29 patients (94{\%}) had thrombocytopenia (platelet count ≤ 100 × 109/L). Seventeen patients (55{\%}) had cytopenia that developed during the course of treatment with fludarabine-based regimens. Nineteen patients (61{\%}) had received prior therapy for this complication using steroids, intravenous immunoglobulin, and/or splenectomy. RESULTS. Eighteen patients (62{\%}) with thrombocytopenia and 10 patients (63{\%}) with anemia had a major response defined as an increase in the platelet count ≥ 50 × 109/L or an increase in hemoglobin ≥ 3 g/dL. The median time to initial response was 3 weeks (range, 1÷-13 weeks) and the median time to best response was 10.5 weeks (range, 1÷-48 weeks). The median duration of response was 10 months (range, 1÷-39+ months). Three patients with fludarabine-associated cytopenias were able to receive further therapy with fludarabine with a lesser decrease in the platelet count. A modest decrease in the tumor burden was observed in six patients. The most common toxicity was ≤ Grade 2 (according to the National Cancer Institute's Common Toxicity Criteria) elevation of creatinine, which was observed in 6 patients (19{\%}). Three patients developed opportunistic infections. CONCLUSIONS. CsA is an effective alternative for the treatment of anemia or thrombocytopenia of suspected autoimmune etiology, including those cases occurring in the course of treatment with fludarabine. A modest antileukemic effect was observed in some patients.",
keywords = "Anemia, Chronic lymphocytic leukemia, Cyclosporine A, Thrombocytopenia",
author = "Jorge Cortes and Susan O'Brien and Javier Loscertales and Hagop Kantarjian and Francis Giles and Deborah Thomas and Charles Koller and Michael Keating",
year = "2001",
month = "10",
day = "15",
doi = "10.1002/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E",
language = "English (US)",
volume = "92",
pages = "2016--2022",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

AU - Cortes, Jorge

AU - O'Brien, Susan

AU - Loscertales, Javier

AU - Kantarjian, Hagop

AU - Giles, Francis

AU - Thomas, Deborah

AU - Koller, Charles

AU - Keating, Michael

PY - 2001/10/15

Y1 - 2001/10/15

N2 - BACKGROUND. Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL. METHODS. Thirty-one patients with CLL and anemia or thrombocytopenia of presumed autoimmune etiology were treated with CsA at a dose of 300 mg/day. Sixteen patients (52%) had anemia (hemoglobin ≤ 11 g/dL) and 29 patients (94%) had thrombocytopenia (platelet count ≤ 100 × 109/L). Seventeen patients (55%) had cytopenia that developed during the course of treatment with fludarabine-based regimens. Nineteen patients (61%) had received prior therapy for this complication using steroids, intravenous immunoglobulin, and/or splenectomy. RESULTS. Eighteen patients (62%) with thrombocytopenia and 10 patients (63%) with anemia had a major response defined as an increase in the platelet count ≥ 50 × 109/L or an increase in hemoglobin ≥ 3 g/dL. The median time to initial response was 3 weeks (range, 1÷-13 weeks) and the median time to best response was 10.5 weeks (range, 1÷-48 weeks). The median duration of response was 10 months (range, 1÷-39+ months). Three patients with fludarabine-associated cytopenias were able to receive further therapy with fludarabine with a lesser decrease in the platelet count. A modest decrease in the tumor burden was observed in six patients. The most common toxicity was ≤ Grade 2 (according to the National Cancer Institute's Common Toxicity Criteria) elevation of creatinine, which was observed in 6 patients (19%). Three patients developed opportunistic infections. CONCLUSIONS. CsA is an effective alternative for the treatment of anemia or thrombocytopenia of suspected autoimmune etiology, including those cases occurring in the course of treatment with fludarabine. A modest antileukemic effect was observed in some patients.

AB - BACKGROUND. Autoimmune cytopenias are a frequent complication in patients with chronic lymphocytic leukemia (CLL). Anecdotal reports suggest that cyclosporin A (CsA) may be beneficial for patients with CLL-associated pure red cell aplasia. In the current study, the authors investigated the use of CsA in the management of anemia or thrombocytopenia of presumed autoimmune etiology associated with CLL. METHODS. Thirty-one patients with CLL and anemia or thrombocytopenia of presumed autoimmune etiology were treated with CsA at a dose of 300 mg/day. Sixteen patients (52%) had anemia (hemoglobin ≤ 11 g/dL) and 29 patients (94%) had thrombocytopenia (platelet count ≤ 100 × 109/L). Seventeen patients (55%) had cytopenia that developed during the course of treatment with fludarabine-based regimens. Nineteen patients (61%) had received prior therapy for this complication using steroids, intravenous immunoglobulin, and/or splenectomy. RESULTS. Eighteen patients (62%) with thrombocytopenia and 10 patients (63%) with anemia had a major response defined as an increase in the platelet count ≥ 50 × 109/L or an increase in hemoglobin ≥ 3 g/dL. The median time to initial response was 3 weeks (range, 1÷-13 weeks) and the median time to best response was 10.5 weeks (range, 1÷-48 weeks). The median duration of response was 10 months (range, 1÷-39+ months). Three patients with fludarabine-associated cytopenias were able to receive further therapy with fludarabine with a lesser decrease in the platelet count. A modest decrease in the tumor burden was observed in six patients. The most common toxicity was ≤ Grade 2 (according to the National Cancer Institute's Common Toxicity Criteria) elevation of creatinine, which was observed in 6 patients (19%). Three patients developed opportunistic infections. CONCLUSIONS. CsA is an effective alternative for the treatment of anemia or thrombocytopenia of suspected autoimmune etiology, including those cases occurring in the course of treatment with fludarabine. A modest antileukemic effect was observed in some patients.

KW - Anemia

KW - Chronic lymphocytic leukemia

KW - Cyclosporine A

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0035886527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035886527&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E

DO - 10.1002/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E

M3 - Article

C2 - 11596014

AN - SCOPUS:0035886527

VL - 92

SP - 2016

EP - 2022

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -